The development of targeted contrast agents such as fluorescent and nanoparticle probes coupled with optical imaging techniques has made it possible to selectively view specific biological events and processes in both in vivo and ex vivo systems with great sensitivity and selectivity. We are continuing to expand our imaging probes to identify key features in nature that hold promise for the development of early disease detection and therapeutics.
